Amplia Therapeutics (ASX:ATX) is an Australian clinical stage pharmaceutical company focused on developing new approaches for the treatment of cancer and fibrosis through two potent and orally-available inhibitors of Focal Adhesion. Ahead of appearing at the Stocks On Track event, Amplia Therapeutics Chief Executive Officer and Managing Director, Chris Burns, joins Lel Smits on The Stock Network.
1. Focal Adhesion Kinase
In simple terms tell us what Focal Adhesion Kinase is, and how Amplia’s drugs could be used to improve the treatment of cancer?
2. Clinical trial on pancreatic cancer
Uou recently completed enrollment for a Phase 2a clinical trial in advanced pancreatic cancer two months ahead of schedule. What are you looking to achieve from this trial and when can we expect to see results?
3. Pancreatic cancer prevalence and addressable market
What are some of the challenges in pancreatic cancer treatment at present, and just how big is the global treatment market for the disease?
_ _ _
Subscribe to TSN’s YouTube channel for the latest stock content: https://www.youtube.com/channel/UCEEVNCMFSRxFa0Bb2wKLS0g?sub_confirmation=1
_ _ _
Follow TSN for the latest stock news and interviews:
Twitter: https://twitter.com/thestocknet
Instagram: https://www.instagram.com/thestocknetwork/
LinkedIn: https://www.linkedin.com/company/the-stock-network/
TikTok: https://www.tiktok.com/@thestocknet?lang=en
Facebook: https://www.facebook.com/TheStockNet/
_ _ _
Connect with our host Lel Smits online – @LelSmits
– Twitter / X: https://twitter.com/lelsmits
– Instagram: https://www.instagram.com/lelsmits/
– LinkedIn: https://www.linkedin.com/in/leldesmits/
– TikTok: https://www.tiktok.com/@lelsmits?lang=en
– Facebook: https://m.facebook.com/lelsmits/
– Threads: https://www.threads.net/@lelsmits
_ _ _
Disclaimer
The material contained in this post is general in nature only and does not constitute personal financial or legal advice. None of our material should be regarded as advice and you should not rely on any of the content of this post without first obtaining specific professional advice. We give no warranty to the accuracy, reliability or completeness of information that is contained in this post and exclude liability for any loss.
This post may contain views and opinions which are those of the authors and do not necessarily reflect the official policy or position of any other author, agency, organisation, employer or company. We are not liable for any comment published by users and reserve the right to delete any comment for any reason whatsoever. We have commercial relationships with some of our contributors, and we may receive payment or other benefits from this post. Please see The Stock Network website for our full content disclaimer.
_ _ _
Visit TSN’s website to sign up for regular stock updates: https://www.thestocknetwork.com.au
_ _ _